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Abstract 12 
The discovery of new drugs with novel targets is paramount to the continued success of 13 
tuberculosis (TB) treatment due to the increasing prevalence of antibiotic resistant infections 14 
in the TB population. Mycobacterium tuberculosis (Mtb) fumarate hydratase (fumarase) is a 15 
highly conserved essential protein which shares an active site with human fumarase, making 16 
active site inhibition equally cytotoxic for both bacteria and humans. The recent discovery of 17 
a set of new Mtb inhibitory compounds that target Mtb-fumarase by binding to a non-conserved 18 
allosteric site is a major advancement, providing further evidence to dispel the antibiotic 19 
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Mycobacterium tuberculosis (Mtb), the causative agent of tuberculosis (TB) is attributed to 1.3 26 
million deaths and 10 million new cases per annum1 and remains one of the top 10 causes of 27 
death worldwide. The treatment strategy for drug-sensitive Mtb infections is a 6 month course 28 
comprising of 4 drugs, isoniazid (INH), rifampicin (RIF), pyrazinamide and ethambutol for the 29 
first two months and INH and RIF for the remaining 4 months, and this strategy has remained 30 
largely unchanged since its advent in the 1980s. Unsurprisingly, there has been a steady 31 
emergence of drug resistance to this frontline strategy, culminating in the identification of 32 
widespread multi-drug resistant TB (MDR-TB), comprising around 5% of newly identified 33 
Mtb infections, wherein resistance to INH and RIF is observed. More concerning still is the 34 
increasing prevalence of extensively drug-resistant TB (XDR-TB), resistant to INH, RIF and 35 
at least 3 injectable second-line drugs (8.5% of new MDR-TB cases)1. This clearly exemplifies 36 
the urgent need to discover new antibiotics that are able to overcome or bypass the resistance 37 
mechanisms that are becoming abundant in Mtb in order to halt the progression of antibiotic 38 
resistance. On page XXX of this issue, authors report the outcome of a successful structure-39 
activity relationship screen, providing a new Mtb inhibitor that targets a non-conserved 40 
allosteric site in the highly conserved fumarase enzyme. Their findings provide new 41 
opportunities for TB drug discovery and a philosophical change in exclusion criteria for what 42 
makes a valuable antibiotic drug target.  43 
 44 
Despite a recent plethora of new Mtb inhibitory molecules, there remains a high attrition rate, 45 
with the majority of new molecules never making it into clinical trial. This is largely due to 46 
early exclusion factors such as the identification of a target protein which is highly 47 
evolutionarily conserved. Widely, the assumption is held that a highly conserved target is 48 
unlikely to yield positive results under clinical trial due to the risk of also inhibiting the human 49 
orthologue. There are recent notable exceptions to the rule in terms of Mtb drug discovery, 50 
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including bedaquiline, the first new TB drug to be approved by the U.S. Food and Drug 51 
Administration (FDA) in 40 years. Bedaquiline (BDQ), a member of the diarylquinoline class 52 
of inhibitors, targets one of the most evolutionarily conserved proteins, the proton pump ATP 53 
synthase. Perhaps unsurprisingly this drug carries a number of serious “black-box warnings” 54 
from the FDA including an increased risk of death and arrhythmias due to off-target effects 55 
blocking the hERG channel and as a result is approved as a drug of last resort for MDR-TB. In 56 
spite of the relatively conserved sequence and structure of ATP synthase, BDQ has been shown 57 
to have much higher specificity for the mycobacterial c-ring of ATP synthase over other 58 
prokaryotic and eukaryotic homologues, where steric hindrance prevents a number of crucial 59 
drug-protein interactions2. Ultimately, this results in significantly higher IC50 values (>200 60 
μM) for eurkaryotic ATP synthases, over mycobacterial homologues (20-25 nM)2. However, 61 
despite the limitations, this drug provides a new treatment option and consequently has been 62 
widely implemented, catalyzing the debate surrounding exclusion of antimicrobial drugs with 63 
conserved targets.  64 
 65 
Bacterial core metabolism presents a number of alluring candidates to target 66 
chemotherapeutically, given the essentiality of the enzymes involved. However, that 67 
enthusiasm is offset by the level of evolutionary conservation with human homologues and 68 
their equal importance for organism viability. Fumarate hydratase (fumarase) catalyzes the 69 
reversible hydration and dehydration of fumarate to malate in the tricarboxylic acid (TCA) 70 
cycle, ultimately driving the production of reduced nicotinamide adenine dinucleotide (NADH) 71 
as well as the metabolic precursors of certain amino acids. Fumarase is a core enzyme in 72 
cellular metabolism and is highly conserved between prokaryotes and eukaryotes. 73 
Furthermore, with a 53% sequence homology to the human ortholog, the Mtb fumarase 74 
presents enough of a challenge to make it an unlikely candidate as an anti-TB drug target. 75 
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Nevertheless, these obstacles failed to deter the Hyvönen, Boshoff, Abell, Barry and Thomas 76 
laboratories to explore a hit molecule from a high-throughput screen.  They previously 77 
identified N-(5-(azepan-1-ylsulfonyl)-2-methoxyphenyl)-2-(4-oxo-3,4-dihydrophthalazin-1-78 
yl)acetamide, otherwise known as compound 7, from a library of just under 500,000 small 79 
molecules using a fumarase-resazurin coupled assay, followed by X-ray crystallography, 80 
which yielded fumarase inhibition at a newly discovered allosteric site. They further 81 
demonstrated that compound 7 showed no inhibition of the human homologue at much higher 82 
concentrations, confirming selectivity3.   83 
 84 
Figure 1: Workflow of Mtb fumarase inhibitor development. A) Complete compound 1 from 85 
HTS screen inhibits Mtb fumarase, but has little whole cell activity against M. tuberculosis 86 
H37Rv. B) Compound 1 was fragmented and screened for activity, but showed no Mtb 87 
fumarase inhibition. C) Derivatives of R-group A were developed and screened, showing 88 
activity against M. tuberculosis H37Rv, but little Mtb fumarase inhibition. D) Derivatives of 89 
R-group D were developed and screened, showing both activity against M. tuberculosis H37Rv 90 




In this latest study, the lead compound, 7 has been renamed as compound 1. The team 94 
conducted hit-to-lead and defragmentation structure-activity relationship screening around 95 
compound 1 with the objective of improving the minimal inhibitory concentration (MIC) from 96 
the previously reported modest inhibitory activity at 250 μM (Figure 1A). Their initial 97 
approach involving the defragmentation of the lead compound (1) into fragment-like molecules 98 
was unyielding in terms of inhibitory activity against Mtb fumarase at concentrations up to 1 99 
mM, which the authors still helpfully included in the manuscript to prevent reproduction of 100 
efforts (Figure 1B)4. However, their structure-activity relationship screen was much more 101 
successful, generating 5 new compounds (15a-d and 16b) with MIC ranging from 19 μM 102 
(compound 16b) to 6.3 μM (compound 15d) in Middlebrook 7H9 media supplemented with 103 
dipalmitoylphosphatidylcholine (DPPC) (Figure 1C/D)4. This choice of supplement is well 104 
justified as it accurately represents the in vivo conditions of Mtb growth, wherein long-chain 105 
fatty acids are catabolized to acetyl-CoA driving metabolic flux into the Krebs cycle. This is 106 
perhaps down to the increase in lipophilicity (cLogP) of the compounds from 1.6 (compound 107 
1) to 4.1 (compounds 15c and 15d) as Mtb-active drugs tend to have poor solubility when 108 
cLogP >4 (for example, bedaquiline cLogP is 7.10).  109 
 110 
The improved MICs of the new compounds from the structure-activity relationship screen 111 
somewhat impacted the inhibition of Mtb fumarase as percentage inhibition of Mtb fumarase 112 
was reduced from >90% (compound 1) to 10-38% (compounds 15a-d), therefore negating IC50 113 
calculations at 50 μM (Figure 1C)4. However, compound 16b gave an IC50 of 4.0 μM (± 0.1), 114 
compared to 2.0 μM (± 0.1) for compound 1, demonstrating that it was indeed possible to 115 
maintain Mtb fumarase inhibitory activity whilst also producing an MIC (Figure 1D)4. Despite 116 
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the significant impact on the inhibitory activity of the target, the fact remains that Whitehouse 117 
et al. have successfully overcome the mycobacterial cell wall permeability barrier with 118 
structural modifications to their hit compound. Furthermore, they have demonstrated that 119 
despite significant homology to the human fumarase enzyme, their inhibition at an unconserved 120 
allosteric site rather than the conserved active site enables a selectivity of their compounds for 121 
Mtb fumarase. There is still a long road ahead for these compounds in terms of progressing 122 
them to any future clinical trial, but in our view this work cuts new ground in Mtb drug 123 
discovery and creates opportunities for reconsidering targets that have been previously 124 
discounted on the basis of homology.   125 
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